A Phase 3, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants

Trial Profile

A Phase 3, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs MDR 101 (Primary)
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Medeor Therapeutics
  • Most Recent Events

    • 27 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 1 Feb 2018.
    • 26 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 22 Jan 2018 Steven R. Deitcher is Principal Investigator for this trial, as reported in a Medeor Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top